Impact News +++ Bridgestone Corporation Profit Climbs In H1 (AFX) +++ BRIDGESTONE Aktie +5,83%

HALOZYME Aktie

>HALOZYME Aktienkurs

78.08 EUR +4.9% (TradegateBSX)

Ask: 78.08 EUR / 39 Stück

Bid: 77.16 EUR / 65 Stück

Tagesumsatz: 969 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

HALOZYME Aktie über LYNX handeln

Intraday

1 Jahr

>HALOZYME Performance

1 Woche: +3,2%

1 Monat: +5,6%

3 Monate: +32,4%

6 Monate: +7,8%

1 Jahr: +38,9%

laufendes Jahr: +26,6%

>HALOZYME Aktie

Profil:

Halozyme Therapeutics Inc. is a biopharmaceutical technology platform company specializing in innovative drug delivery solutions. The company focuses on enhancing the administration of biologic and other injectable therapies through its proprietary E..
>Volltext..

Insiderhandel:

>HALOZYME Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>HALOZYME Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>HALOZYME Chart & Kurs - Tradegate

>HALOZYME News

07.08.26 - 01:33	Halozyme projects 2026 non-GAAP EPS of $8.65-$9.00 while raising revenue outlook to $1.835B-$1.91B (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.26 - 23:54	Earnings Call: Halozyme übertrifft Schätzungen für Q2 2026 und hebt Prognose an (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.26 - 23:48	Earnings Call: Halozyme übertrifft Q2-2026-Prognosen und hebt Ausblick an (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.26 - 22:06	Halozyme Therapeutics Non-GAAP EPS of $2.28 beats by $0.46, revenue of $481M beats by $78.72M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.07.26 - 19:30	Keine Ende der Rallye in Sicht: Diese Biotechnologie-Aktie bietet für ihr Geld so viel wie kaum eine zweite! (Wallstreet-Online)
	Trotz eines enorm starken Wachstums und einer günstigen Unternehmensbewertung ist Halozyme noch immer ein Nischenwert. Das dürfte nicht mehr lange so bleiben....

23.07.26 - 14:33	Halozyme to Report Second Quarter 2026 Financial and Operating Results (PR Newswire)
	SAN DIEGO, July 23, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, following the close of trading. Halozyme will host a conference call on......

21.07.26 - 18:15	HALO Inks Deal With INCY to Support Cancer Therapy Development (Zacks)
	Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients....

21.07.26 - 11:24	Halozyme and Incyte sign licence agreement for INCA033989 formulations (PBR)
	The partnership will use Halozyme's Enhanze drug delivery technology to potentially improve the convenience of administering INCA033989. Incyte will evaluate the benefits of the technology in creating subcutaneous The post Halozyme and Incyte sign licence agreement for INCA033989 formulations appeared first on Pharmaceutical Business review....

20.07.26 - 14:51	Halozyme in deal with Incyte to use Enhanze technology for neoplasms candidate (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

20.07.26 - 14:31	Halozyme Partners Incyte To Devolop Subcutaneous Formulations Of INCA033989 Using ENHANZE Technology (AFX)
	WASHINGTON (dpa-AFX) - Biopharmaceutical company Halozyme Therapeutics, Inc. (HALO) announced Monday that it has entered into a global collaboration and license agreement with Incyte Corp. (INCY) ......

20.07.26 - 14:12	Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology (PR Newswire)
	Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targets SAN DIEGO, July 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today......

02.07.26 - 23:36	Halozyme: COO-Abgang belastet Aktie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

30.06.26 - 22:06	Halozyme Appoints David Ramsay as President Drug Delivery (PR Newswire)
	SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, effective June 30, 2026. In this newly created role, Mr. Ramsay will have an enterprise-wide,......

15.06.26 - 12:03	Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 (PR Newswire)
	SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program......

10.06.26 - 19:00	Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue? (Zacks)
	Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

26.05.26 - 16:45	Implied Volatility Surging for Halozyme Therapeutics Stock Options (Zacks)
	Investors need to pay close attention to HALO stock based on the movements in the options market lately....

12.05.26 - 19:45	Halozyme′s Q1 Earnings & Revenues Beat Estimates, Stock Up (Zacks)
	HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year....

12.05.26 - 04:57	Halozyme outlines ENHANZE royalties exceeding $1B in 2026 while launching a new $1B buyback (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.05.26 - 04:48	Halozyme (HALO) Q1 2026 Earnings Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

12.05.26 - 01:00	Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
	While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Ubi lex, ibi poena - Wo ein Gesetz, da auch eine Strafandrohung. - Nomen Nescio

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram